[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pet--mr\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pet--mr":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,49,73,95,120],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":4},"100635401","comparison-of-68gaga-ctr-fapi-and-18f-fdg-petmri-for-lymph-node-staging-in-rectal-cancer-100635401",false,"NCT07552207","Comparison of [68Ga]Ga-CTR-FAPI and 18F-FDG PET\u002FMRI for Lymph Node Staging in Rectal Cancer","Comparison of the Diagnostic Efficacy of [68Ga]Ga-CTR-FAPI PET\u002FMRI and 18F-FDG PET\u002FMRI for Lymph Node Metastasis in Middle to High Rectal Cancer","PKUCH-R12","Inclusion Criteria:\n\n* Confirmed rectal adenocarcinoma by pathological biopsy.\n* Lower margin of the tumor is ≥ 5 cm and ≤15 cm from the anal verge.\n* Planned to undergo radical surgery.\n* ECOG performance status score ≤ 2.\n* Patient is willing to undergo PET\u002FMRI examination.\n\nExclusion Criteria:\n\n* History of pelvic radiotherapy or chemotherapy.\n* Concurrent with other malignant tumors or active infections.\n* Pregnant or unable to sign the informed consent form.\n* Claustrophobia or inability to tolerate MRI examinations due to other reasons.","ALL","18 Years","75 Years",{"count":21,"type":22},30,"ESTIMATED","INTERVENTIONAL",[25],"NA","This is a prospective, single-center, diagnostic study designed to compare the accuracy of \\[68Ga\\]Ga-CTR-FAPI PET\u002FMRI and \\[18\\]F-FDG PET\u002FMRI for the detection of lymph node metastasis in patients with initially untreated, resectable middle to high rectal cancer. The study aims to evaluate whether \\[68Ga\\]Ga-CTR-FAPI PET\u002FMRI provides higher sensitivity and specificity than traditional 18F-FDG PET\u002FMRI at both the patient level and the lymph node level.",[28,29,30],"Rectal Cancer","Lymph Node Metastases","PET \u002F MR",[32,33,34,35,36],"PET\u002FMR","[68Ga]Ga-CTR-FAPI","18F-FDG","Lymph Node Staging","Radiomics","NOT_YET_RECRUITING","2026-04-28",{"date":40,"type":41},"2026-05-04","ACTUAL",{"date":43,"type":22},"2026-04-01",{"date":45,"type":22},"2028-12-31",{"name":47,"class":48},"Peking University Cancer Hospital & Institute","OTHER",{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":55,"sex":17,"minAge":18,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":23,"phases":59,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":72},"100635891","research-on-the-application-of-sigma-radiopharmaceutical-fbfp-in-cerebral-stroke-100635891","NCT07558577","Research on the Application of Sigma Radiopharmaceutical FBFP in Cerebral Stroke","Inclusion Criteria:\n\n1. Angiography diagnosis shows unilateral anterior circulation head and neck artery stenosis with a diameter reduction of\\>70%, and there is no stenosis in the contralateral anterior circulation or bilateral posterior circulation with a diameter reduction of\\>50%;\n2. Transient ischemic attack or ischemic stroke that must have occurred within the past 12 months in the affected vascular area, with the most recent attack lasting more than 3 weeks;\n3. MRI shows no new intracranial infarction lesions;\n4. No previous infarction lesions in the pontine area;\n5. Either PET\u002FMR blood flow or metabolic imaging shows reduced blood flow and metabolism in the affected hemisphere, with a reduction rate exceeding 10% compared to the contralateral region;\n6. Subjects and informants can complete relevant examinations and follow-up work;\n7. The subject or their authorized representative signs the informed consent form.\n\nExclusion Criteria:\n\n1. Poor image quality due to head movement and other reasons during the scanning process.\n2. There are other neurological disorders that can cause brain dysfunction, such as depression, brain tumors, Parkinson's disease, metabolic encephalopathy, encephalitis, multiple sclerosis, epilepsy, traumatic brain injury, normal intracranial pressure hydrocephalus, etc.\n3. There are other systemic diseases that can cause cognitive impairment, such as liver dysfunction, kidney dysfunction, thyroid dysfunction, severe anemia, folate and vitamin B12 deficiency, special infections (such as syphilis, HIV), alcohol and drug abuse, etc.\n4. Existence of mental and neurological developmental delay.\n5. There are other known diseases that may cause cognitive impairment.\n6. Individuals with severe visual and hearing impairments, claustrophobia, and other conditions who cannot cooperate with MRI examinations.\n7. Suffering from diseases that prevent cooperation in completing cognitive examinations.\n8. Refusal to sign informed consent form during baseline period -",true,"99 Years",{"count":58,"type":22},50,[25],"This clinical research, aims to investigate the uptake of \\[18F\\]FBFP, a Sigma-1 receptor (Sig 1R) PET imaging agent, in stroke participants, compare differences with healthy controls, and evaluate its diagnostic efficacy, providing objective basis for clinical diagnosis and treatment.\n\nThe study will recruit 30 stroke participants (with specific inclusion criteria for unilateral ICA stenosis cases) and 20 gender- and age-matched healthy controls from January 2025 to December 2026. Exclusion criteria cover various neurological and systemic diseases that may affect results, as well as conditions preventing cooperation with examinations.\n\nNo intervention measures are involved. Follow-ups will be conducted at 6 and 12 months to collect clinical data and observe neurological symptom progression. Key measurements include clinical information (via questionnaires and scales like NIHSS and mRS) and PET\u002FMR imaging data (analyzed using PMOD software to calculate SUVmean and uptake differences with cerebellar cortex as reference).\n\nStatistical analysis will use SPSS 21.0, applying descriptive statistics, t-test, ANOVA, regression models, ROC curves, etc., with P \\\u003C 0.05 as significant. Safety evaluation notes PET\u002FMR radiation dose (3-5mSv) is much lower than the safe threshold.\n\nParticipant protection includes ethical approval, informed consent, voluntary participation, risk disclosure, no fees for related exams, and privacy protection. The research team and institution have sufficient resources and qualifications, with outputs including a clinical research cohort and a high-quality paper.",[62,30],"Cerebral Ischemia","2026-04-26",{"date":65,"type":41},"2026-04-30",{"date":67,"type":22},"2026-06-01",{"date":69,"type":22},"2026-12-31",{"name":71,"class":48},"Xuanwu Hospital, Beijing",1,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":55,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":79,"targetDuration":4,"studyType":81,"phases":4,"briefSummary":82,"conditions":83,"keywords":4,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":93,"locationsCount":72},"100593302","18f-fdg-and-68ga-fapi-petmr-imaging-of-carotid-artery-plaque-vulnerability-a-clinical-study-in-carotid-artery-plaque-patients-100593302","NCT07004673","18F FDG and 68Ga FAPI PET\u002FMR Imaging of Carotid Artery Plaque Vulnerability: A Clinical Study in Carotid Artery Plaque Patients","Inclusion Criteria:\n\n-Age between 18 and 80 years; Presence of carotid atherosclerotic plaque confirmed by ultrasound within the past two weeks, with carotid intima-media thickness (IMT) ≥ 2 mm (IMT ≥ 1.2 mm is defined as carotid atherosclerosis) or carotid artery stenosis ≥ 50% as indicated by CTA.\n\nExclusion Criteria:\n\n* Absolute or relative contraindications related to PET\u002FMR imaging safety (e.g., metallic implants, MRI phobia, etc.); Patients who have undergone carotid endarterectomy (CEA) or carotid artery stenting (CAS); Pregnant or lactating women; Presence of other vascular diseases, such as vasculitis, moyamoya disease, arterial dissection, etc.; Severe agitation or inability to cooperate with imaging procedures.",{"count":80,"type":22},100,"OBSERVATIONAL","Carotid atherosclerotic plaque rupture is the main cause of ischemic stroke attacks, and early and precise assessment of plaque vulnerability can prevent ischemic stroke. High-resolution MRI can reflect vulnerable plaque features such as thin fibrous caps and large lipid cores, but cannot assess their metabolic information; Fibro-activated proteins (FAPs) of PET are specifically expressed in atherosclerosis and suggest vulnerable plaques by reflecting inflammation-induced fibrosis. The aim of this study was to apply 18F FDG\\&68Ga-FAPI PET\u002FMR imaging to investigate the vulnerability of carotid atherosclerotic plaques, to obtain quantitative evaluation indexes of active fibrosis within carotid plaques, and to clarify the PET\u002FMR characteristics of unstable plaques in carotid arteries",[84,85,30],"Carotid Artery Plaque","Ischemic Stroke","RECRUITING","2026-03-03",{"date":89,"type":41},"2026-03-05",{"date":91,"type":41},"2025-04-12",{"date":69,"type":22},{"name":94,"class":48},"Ruijin Hospital",{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":99,"acronym":4,"eligibilityCriteria":100,"healthyVolunteers":55,"sex":17,"minAge":18,"maxAge":101,"enrollmentInfo":102,"targetDuration":104,"studyType":81,"phases":4,"briefSummary":105,"conditions":106,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":4},"100604268","multimodal-pet-imaging-with-18f-fdgsv2atspo-for-resection-planning-in-drug-resistant-epilepsy-100604268","NCT07147309","Multimodal PET Imaging With 18F-FDG\u002FSV2A\u002FTSPO for Resection Planning in Drug-Resistant Epilepsy","Inclusion Criteria:\n\n* with drug-resistant focal epilepsy defined by ILAE criteria\n* Already performed 3.0 T epilepsy-protocol MRI and video-EEG\n* Planned resective surgery or stereotactic EEG (SEEG) electrode implantation, and willingness to undergo all three PET scans: ¹⁸F-FDG, SV2A, and TSPO.\n* Ability to understand study procedures and provide written informed consent.\n* Availability of complete postoperative follow-up data with at least 12-month Engel outcome classification.\n\nExclusion Criteria:\n\n-History of head trauma ,claustrophobia, rheumatic or autoimmune diseases, psychiatric disorders, severe somatic diseases (neurological,cardiovascular, etc.),previous heart or brain surgery, substance abuse, inability to refrain from hypnotics, magnetic implants, pregnancy, lactation","50 Years",{"count":103,"type":22},60,"2 Years","This study focuses on the application value of 18F-FDG, SV2A, and TSPO PET imaging in the preoperative localization of epileptogenic foci in epilepsy. 18F-FDG PET detects glucose metabolism in brain tissue and is characterized by reduced metabolism during the interictal period. It is currently the most commonly used localization method in clinical practice, especially suitable for temporal lobe epilepsy, but has limited sensitivity to foci with insignificant metabolic changes. SV2A PET targets synaptic vesicle proteins and reflects synaptic density, showing reduced uptake in epileptogenic foci areas. It has high localization accuracy, can effectively supplement the diagnosis of 18F-FDG PET-negative cases, and also has good application prospects in non-temporal lobe epilepsy. TSPO PET monitors microglial activation to reflect neuroinflammation, with increased uptake in epileptogenic foci areas, and has unique auxiliary diagnostic value in refractory epilepsy and cases with concurrent brain injury. The combined application of the three can provide a more comprehensive imaging basis for preoperative localization of epilepsy, helping to optimize surgical plans.",[107,30,108,109,110],"Epilepsy","Synaptic Vesicle Proteins","Microglial Activation","FDG PET","2025-08-28",{"date":113,"type":41},"2025-08-29",{"date":115,"type":22},"2025-09-01",{"date":117,"type":22},"2029-09-01",{"name":119,"class":48},"Weibing Miao, PhD",{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":124,"acronym":4,"eligibilityCriteria":125,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":126,"enrollmentInfo":127,"targetDuration":4,"studyType":81,"phases":4,"briefSummary":129,"conditions":130,"keywords":4,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":139,"locationsCount":72},"100602968","multimodal-imaging-assessment-after-revascularization-in-patients-with-acute-myocardial-infarction-100602968","NCT07130409","Multimodal Imaging Assessment After Revascularization in Patients With Acute Myocardial Infarction","Inclusion Criteria:\n\n* Patients with a clinical diagnosis of first-episode acute myocardial infarction (AMI) who underwent emergency percutaneous coronary intervention (PCI) were included. All patients had complete baseline clinical data, with baseline cardiac magnetic resonance (CMR) examinations performed within 7 days post-PCI and follow-up CMR completed at 6 months post-procedure.\n\nExclusion Criteria:\n\n* Patients with severe cardiac decompensation (Killip class 4) or clinically unstable conditions.\n\nPatients with coexisting valvular heart disease, congenital heart disease, pulmonary hypertension, cardiomyopathy, or persistent atrial fibrillation that may confound cardiac structural\u002Ffunctional assessments.\n\nPrior history of myocardial infarction, coronary revascularization (PCI\u002FCABG).\n\nConcurrent severe systemic diseases including hematologic disorders, malignancies, rheumatic\u002Fautoimmune diseases, or severe hepatic\u002Frenal failure.\n\nContraindications to CMR (claustrophobia, pacemaker implantation, etc.).\n\nPregnant, breastfeeding, or women of childbearing potential without effective contraception.\n\nSexually active individuals of reproductive age unwilling to use reliable contraception.","80 Years",{"count":128,"type":22},20,"This prospective cohort study will enroll 20 patients clinically diagnosed with first-time acute myocardial infarction (AMI) who underwent interventional procedures (including percutaneous coronary intervention \\[PCI\\] and balloon angioplasty) at the Affiliated Hospital of Qingdao University. Patient data, including routine blood and urine tests, blood biochemistry, electrocardiograms (ECG), imaging studies, and interventional procedure records, will be collected to assess eligibility for enrollment. The study procedures include patient screening and enrollment, obtaining informed consent, baseline assessment (including medical history, laboratory tests, ECG, etc.), an ¹⁸F-Pentixafor PET\u002FMR examination, and follow-up. Images will be blindly assessed by at least two specialized physicians from the Radiology and Nuclear Medicine departments. The study aims to investigate the utility of ¹⁸F-Pentixafor PET\u002FMR in evaluating coronary microcirculatory function, cardiac function, myocardial viability, myocardial inflammatory response, and the efficacy of interventional therapy in AMI patients post-procedure. Additionally, it will perform risk stratification and prognostic analysis for the enrolled patients.",[131,132,30],"Cardiac Magnetic Resonance Imaging","Acute Myocardial Infarction (AMI)","2025-08-15",{"date":135,"type":41},"2025-08-19",{"date":137,"type":22},"2025-08",{"date":69,"type":22},{"name":140,"class":48},"The Affiliated Hospital of Qingdao University"]